The pivotal guardian(TM) clinical programme was one of the largest and most comprehensive preregistration clinical trial programmes in haemophilia
A, with more than 210 patients with severe haemophilia
is an inherited condition that influences the blood's ability to clot.
is a genetic disease affecting over 6,800 people in the UK and around 400,000 worldwide.
This research service focuses on the global haemophilia
therapeutics market, with a particular focus on recently FDA-approved drugs and late-stage compounds for the treatment of haemophilia
B, inhibitors, and von Willebrand Disease.
Even as the country emphasizes on headline-grabbing ailments, haemophilia
, a little known blood disorder, is turning out to be a plague with over 50,000 people affected.
A Canada High Commission release said the event will provide physicians, nurses and families of patients suffering from haemophilia
with important information about the diagnosis and management of the disease and will help raise the profile of haemophilia
within the Delhi medical community.
The management of haemophilia
in developed countries has proceeded through hospital treatment, home therapy, secondary prophylaxis to most costly but very effective primary prophylaxis.
Fore Pharma's latest report 'Global Haemophilia
Drug Pipeline Capsule - 2012 Update' provides most up-to-date information on key Research and Development activities (R&D) in the global Haemophilia
Do inhibitors, treatment regimen and bleed frequency impact parent-directed haemophilia
treatment centre and provider utilisation: An analysis of parents of children with haemophilia
in the HERO study.
comprehensive care model, which is defined as the continuing supervision of all medical and psychosocial factors affecting patients and their families, has been a cornerstone and one of the most successful health programmes in developed countries, resulting in a significant improvement of health and, ultimately, of life expectancy for haemophilia
For Pharma's latest report Global Haemophilia
Drug Pipeline Capsule - 2011' is an outline of all the key research and development (R&D) activities of the global haemophilia
Today, Novo Nordisk announced a new analysis of phase 3 data demonstrating people with haemophilia
A who had the highest annualised bleeding rate (ABR) during initial treatment with NovoEight[sup.